Pasithea Therapeutics (KTTA) Projected to Announce Earnings on Thursday

Pasithea Therapeutics (NASDAQ:KTTA) is projected to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Pasithea Therapeutics to post earnings of ($0.21) per share and revenue of $0.20 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Pasithea Therapeutics (NASDAQ:KTTA) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). On average, analysts expect Pasithea Therapeutics to post ($0.76) EPS for the current fiscal year and ($0.46) EPS for the next fiscal year.

Pasithea Therapeutics Stock Performance

Shares of KTTA stock opened at $0.57 on Wednesday. The firm’s 50 day moving average is $0.48 and its 200 day moving average is $0.62. Pasithea Therapeutics has a 12-month low of $0.28 and a 12-month high of $2.06.

Analyst Ratings Changes

Several research analysts have weighed in on KTTA shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pasithea Therapeutics in a research report on Monday, September 21st. Zacks Research downgraded Pasithea Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pasithea Therapeutics has a consensus rating of “Hold” and an average target price of $3.00.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp. is a biotechnology company focused on developing treatments for central nervous system (CNS) disorders. Its research has centered on novel therapies for conditions such as depression and other neuropsychiatric diseases, areas in which existing treatments may not provide adequate results for all patients. The company has also pursued psychedelic-based therapeutic approaches and related clinical-development programs. In addition to drug discovery, Pasithea has explored treatment-delivery activities, including ketamine-assisted therapy services through operations associated with its business.